Cargando…

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

Detalles Bibliográficos
Autores principales:	Wainberg, Mark A, Mesplede, Thibault
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2015
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671285/ https://www.ncbi.nlm.nih.gov/pubmed/26642452 http://dx.doi.org/10.7448/IAS.18.1.20824

Ejemplares similares

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

Will drug resistance against dolutegravir in initial therapy ever occur?
por: Wainberg, Mark A., et al.
Publicado: (2015)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
por: Mesplède, Thibault, et al.
Publicado: (2018)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

What if HIV were unable to develop resistance against a new therapeutic agent?
por: Wainberg, Mark A, et al.
Publicado: (2013)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Will LEDGIN molecules be able to play a role in a cure for HIV infection?
por: Mesplède, Thibault, et al.
Publicado: (2016)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Women, culture and the HIV epidemic in MENA
por: Chahil-Graf, Renu, et al.
Publicado: (2014)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

The HIV epidemic and human rights violations in Brazil
por: Malta, Monica, et al.
Publicado: (2013)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Barriers to mental healthcare and treatment for people living with HIV in the Asia‐Pacific
por: Sohn, Annette H, et al.
Publicado: (2018)

The Rheumatologist’s Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future
por: Koutsianas, Christos, et al.
Publicado: (2020)

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review
por: Hassounah, Said A., et al.
Publicado: (2016)

Paediatric HIV treatment failure: a silent epidemic
por: Bernheimer, Jonathan M, et al.
Publicado: (2015)

The Enigma of the Human Immunodeficiency Virus (HIV) Epidemic in China
por: Wu, Zunyou, et al.
Publicado: (2020)

The approval of the first malaria vaccine: The beginning of the end of the malaria epidemic
por: Olufadewa, Isaac, et al.
Publicado: (2022)

Digital Health Equity and COVID-19: The Innovation Curve Cannot Reinforce the Social Gradient of Health
por: Crawford, Allison, et al.
Publicado: (2020)

Myosin motors that cannot bind actin leave their folded OFF state on activation of skeletal muscle
por: Reconditi, Massimo, et al.
Publicado: (2021)

Intersecting HIV and mpox epidemics: more questions than answers
por: Girometti, Nicolo, et al.
Publicado: (2022)

World Mental Health Day 2023: We must leave no one behind in the response to HIV and mental health
por: Wainberg, Milton L., et al.
Publicado: (2023)

Reframing the approach to heterosexual men in the HIV epidemic in sub‐Saharan Africa
por: Makusha, Tawanda, et al.
Publicado: (2020)

Research Priorities to End the Adolescent HIV Epidemic in the United States: Viewpoint
por: Fernandez, M Isabel, et al.
Publicado: (2021)

Putting women in the centre of the global HIV response is key to achieving epidemic control!
por: Abdool Karim, Quarraisha, et al.
Publicado: (2020)

The responsibility of thwarting and managing Japanese encephalitis cannot be understated—Outbreaks or resurgences may manifest, catching us off guard
por: Wang, Ran, et al.
Publicado: (2023)

The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead
por: Crabtree‐Ramírez, Brenda, et al.
Publicado: (2020)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

UNGASS 2016 on drugs, the first challenge for HIV advocates in the post-2015 era
por: Fordham, Ann, et al.
Publicado: (2014)

Strengthening Routine Data Systems to Track the HIV Epidemic and Guide the Response in Sub-Saharan Africa
por: Rice, Brian, et al.
Publicado: (2018)

Korotkoff Sounds - The Improbable also Occurs
por: Estañol, Bruno, et al.
Publicado: (2013)

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
por: van Kampen, Jeroen J.A., et al.
Publicado: (2022)

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency
por: Bastarache, Sophie M., et al.
Publicado: (2014)

Ageing with HIV: health implications and evolving care needs
por: Ahmad, Ahsan, et al.
Publicado: (2020)

Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics
por: Read, Sarah W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agag4ot3ld85q71tg1egdsdf2p